Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$18.30
+0.9%
$20.24
$10.21
$25.67
$4.36B0.433.71 million shs1.05 million shs
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$1.33
0.0%
$1.71
$1.09
$7.67
$15.99M0.5350,810 shs12,568 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$35.35
-0.6%
$32.40
$6.76
$46.98
$3.42B0.331.30 million shs481,993 shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$0.77
+0.1%
$0.87
$0.52
$5.17
$64.46M1.641.14 million shs141,879 shs
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
$1.48
$1.65
$0.82
$3.88
$58.11M1.95494,777 shsN/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.00%+0.74%-8.25%+1.58%+63.20%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
0.00%+10.83%-28.88%-36.36%-74.67%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.00%-1.28%+3.21%+31.41%+354.95%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
0.00%+4.22%-7.19%+41.12%-73.44%
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
4.1564 of 5 stars
3.72.00.00.03.02.53.1
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
4.123 of 5 stars
3.55.00.04.30.61.70.0
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.3382 of 5 stars
2.60.00.04.41.13.30.6
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3.1856 of 5 stars
3.11.00.04.70.61.70.0
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6751.23% Upside
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
3.00
Buy$4.00200.75% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.14
Buy$42.6720.70% Upside
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
2.25
Hold$6.11699.25% Upside
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ADMA, STRO, CASI, SRRK, and TCRR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$50.00
6/16/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$2.00
6/3/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/19/2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
5/19/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.80
5/14/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$50.00
5/8/2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.00
4/29/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
4/9/2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $4.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$426.45M10.24$0.54 per share33.77$1.48 per share12.36
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$28.54M0.57N/AN/A$0.12 per share11.08
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$33.19M101.13N/AN/A$3.94 per share8.97
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$62.04M1.04N/AN/A$0.54 per share1.42
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/AN/AN/AN/A$2.58 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8521.5226.51N/A45.01%47.16%30.51%8/6/2025 (Estimated)
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$39.26M-$2.55N/AN/A-129.05%-972.55%-77.33%8/15/2025 (Estimated)
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$227.46M-$2.98N/AN/AN/A-373.66%-347.60%-59.46%8/12/2025 (Estimated)
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/A

Latest ADMA, STRO, CASI, SRRK, and TCRR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/16/2025Q1 2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$0.61-$0.69-$0.08-$0.69$7.39 million$6.24 million
5/14/2025Q1 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.63-$0.67-$0.04-$0.67N/AN/A
5/8/2025Q1 2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million
5/7/2025Q1 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.16$0.14-$0.02$0.11$116.40 million$114.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/AN/AN/AN/AN/A
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.22
6.58
3.36
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/A
0.81
0.68
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.16
10.25
10.25
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/A
2.16
2.16
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
N/A
2.96
2.96

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
22.23%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
96.99%
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
64.76%

Insider Ownership

CompanyInsider Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.70%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
21.24%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
13.30%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
5.90%
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
25.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.73 million229.90 millionOptionable
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
18012.30 million9.69 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
14094.95 million82.32 millionOptionable
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
24084.46 million79.48 millionOptionable
TCR2 Therapeutics Inc. stock logo
TCRR
TCR2 Therapeutics
13739.26 million29.44 millionNot Optionable

Recent News About These Companies

Poseida Therapeutics Inc Ordinary Shares PSTX
DICE Therapeutics Inc.
TCR2 Therapeutics Insider Trades Send a Signal
Recap: TCR2 Therapeutics Q1 Earnings
10-Q: TCR2 THERAPEUTICS INC.
Mizuho Downgrades Tcr2 Therapeutics (TCRR)
4 Analysts Have This to Say About TCR2 Therapeutics
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$18.30 +0.16 (+0.85%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$18.27 -0.03 (-0.14%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CASI Pharmaceuticals stock logo

CASI Pharmaceuticals NASDAQ:CASI

$1.33 0.00 (-0.02%)
Closing price 07/3/2025 03:17 PM Eastern
Extended Trading
$1.33 0.00 (0.00%)
As of 07/3/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$35.35 -0.20 (-0.56%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$35.35 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Sutro Biopharma stock logo

Sutro Biopharma NASDAQ:STRO

$0.76 +0.00 (+0.13%)
As of 07/3/2025 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

TCR2 Therapeutics stock logo

TCR2 Therapeutics NASDAQ:TCRR

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.